{"id":"estetrol-and-drospirenone","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Breakthrough bleeding"},{"rate":null,"effect":"Mood changes"}]},"_chembl":null,"_dailymed":{"setId":"c5270073-d083-4109-ae4b-156986175e0a","title":"NEXTSTELLIS (DROSPIRENONE AND ESTETROL) KIT [MAYNE PHARMA]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Estetrol is a natural estrogen produced during pregnancy that acts as an estrogen receptor agonist, while drospirenone is a progestin with antimineralocorticoid properties. Together they suppress the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) surges needed for ovulation, and alter cervical mucus and endometrial conditions to prevent fertilization and implantation.","oneSentence":"Estetrol and drospirenone work together as a hormonal contraceptive, with estetrol providing estrogenic activity and drospirenone providing progestagenic activity to prevent ovulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:52:00.838Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception in women of reproductive age"}]},"trialDetails":[{"nctId":"NCT06186271","phase":"","title":"International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2025-04-24","conditions":"Contraception","enrollment":68100},{"nctId":"NCT06028555","phase":"","title":"International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2023-06-28","conditions":"Contraception, Birth Control","enrollment":101000},{"nctId":"NCT07061093","phase":"","title":"Prospective Evaluation on the Role Exerted by Hormonal Contraceptives on 24-h Blood Pressure. A Prospective Observational Study","status":"RECRUITING","sponsor":"Ospedale Policlinico San Martino","startDate":"2023-10-10","conditions":"Cardiovascular System Diseases (&Amp; [Cardiac])","enrollment":96},{"nctId":"NCT06396221","phase":"NA","title":"\"Quick-starting\" of a New Combined Hormonal Contraceptive Pills, 15 mg Estetrol/3 mg Drospirenone VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2024-05-01","conditions":"Ultrasound Finding: Ovulation Inhibition, Ovarian Activities, Cervical Mucus, Serum Hormonal Profile","enrollment":36},{"nctId":"NCT05837624","phase":"PHASE4","title":"Estetrol/Drospirenone to Reduce the Average Size of Endometriomas","status":"RECRUITING","sponsor":"Andrew Zakhari","startDate":"2024-12-03","conditions":"Ovarian Endometrioma, Endometrioma","enrollment":21},{"nctId":"NCT06324851","phase":"PHASE4","title":"The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2023-01-01","conditions":"Endometrial Polyp, Endometrial Diseases","enrollment":150},{"nctId":"NCT06316180","phase":"PHASE4","title":"The Use of Drospirenone/Estetrol in Random Start Rapid Endometrial Preparation","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2023-01-01","conditions":"Endometrial Polyp, Endometrial Diseases","enrollment":80},{"nctId":"NCT04792385","phase":"PHASE3","title":"Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents","status":"COMPLETED","sponsor":"Estetra","startDate":"2020-12-28","conditions":"Safety","enrollment":145},{"nctId":"NCT03091595","phase":"PHASE2","title":"E4/DRSP Ovarian Function Inhibition Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2017-02-07","conditions":"Prevention of Pregnancy","enrollment":82},{"nctId":"NCT05677035","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects","status":"COMPLETED","sponsor":"Hyundai Pharm","startDate":"2022-01-11","conditions":"Contraception","enrollment":20},{"nctId":"NCT02817841","phase":"PHASE3","title":"E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-08-30","conditions":"Contraception","enrollment":2148},{"nctId":"NCT02817828","phase":"PHASE3","title":"E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-06","conditions":"Contraception","enrollment":1577},{"nctId":"NCT03512860","phase":"PHASE1","title":"Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2018-04-12","conditions":"Contraception","enrollment":24},{"nctId":"NCT02957630","phase":"PHASE1, PHASE2","title":"\"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study\"","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-09","conditions":"Contraception, Liver Metabolism, Hemostasis Parameter","enrollment":101},{"nctId":"NCT02874248","phase":"PHASE1","title":"E4/DRSP Single and Multiple Dose PK and Early QT Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-05","conditions":"Contraception","enrollment":55},{"nctId":"NCT02852681","phase":"PHASE1","title":"Effect of Food on the Bioavailability of 15 mg Estetrol/3 mg Drospirenone Tablets in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Estetra","startDate":"2015-08","conditions":"Contraception","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Estetrol and Drospirenone","genericName":"Estetrol and Drospirenone","companyName":"Ospedale Policlinico San Martino","companyId":"ospedale-policlinico-san-martino","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Estetrol and drospirenone work together as a hormonal contraceptive, with estetrol providing estrogenic activity and drospirenone providing progestagenic activity to prevent ovulation. Used for Contraception in women of reproductive age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}